These newly cancer-relevant genes have already known functions in regulating immune response (AP2M1, DCTN1, CCT4, DYNC1I2, and DYNC1LI2), kinase binding (DLG3), cell cycle progression (SEC13, ANAPC7, CDC26, PSMC3, PPP1CC), DNA repair (PPIE, RFC5, POLR2E, and POLR2L), cell death (VAPA), and mRNA splicing (SF3A2). The gene discussed is AP2M1; the disease is cancer.